Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

24.20 -0.30 (-1.20%)

Delayed Quote Updated: 11:05 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

5 Top Stocks for February ↗

January 29, 2023

These growth stocks have more room to run.

Via The Motley Fool

3 Great Growth Stocks Down 20% or More to Buy Now ↗

January 27, 2023

These beaten-down stocks could be poised for major rebounds.

Via The Motley Fool

A New Bull Market Is Coming: 3 Stocks That Could Skyrocket ↗

January 21, 2023

Aggressive investors should check out these stocks.

Via The Motley Fool

3 Stocks That Could Create Lasting Generational Wealth ↗

January 15, 2023

Making money that spans generations requires thinking big.

Via The Motley Fool

4 Analysts Have This to Say About Beam Therapeutics ↗

December 20, 2022

Via Benzinga

BMO Capital Upgrades Beam Therapeutics: Here's What You Need To Know ↗

December 20, 2022

Via Benzinga

Beam Therapeutics's Return On Capital Employed Insights ↗

November 30, 2022

Via Benzinga

Beam Therapeutics Temporarily Retreats Clinical Plans For Second Sickle Cell Gene Therapy ↗

November 07, 2022

Via Benzinga

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

January 09, 2023

From Beam Therapeutics

Via GlobeNewswire

Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗

January 04, 2023

Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams.

Via Benzinga

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From Beam Therapeutics

Via GlobeNewswire

3 Under-the-Radar Biotech Stocks to Buy in 2022 ↗

December 24, 2022

The attraction of all three biotech stocks is their potential.

Via The Motley Fool

Why Beam Therapeutics Stock Is Falling Today ↗

November 07, 2022

Beam's decision not to move forward with sickle cell treatment BEAM-102 isn't sitting well with investors today.

Via The Motley Fool

Analyst Beefs Up Beam Therapeutics Price Target, Says 'Reward Is Now Skewed To Upside' ↗

December 20, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 ↗

December 20, 2022

Via Benzinga

Tesla To $285? Here Are 10 Other Price Target Changes For Tuesday ↗

December 20, 2022

Wells Fargo raised Ross Stores, Inc. (NASDAQ: ROST) price target from $120 to $135. Wells Fargo analyst Ike Boruchow maintained an Overweight rating on the stock. Ross Stores shares fell 0.9% to close...

Via Benzinga

7 ‘Next Big Things’ for Investors to Buy for 2023 ↗

December 13, 2022

The next big thing for investors in 2023 is buying companies with revenue expansion amid what could be a painful economic slowdown.

Via InvestorPlace

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

December 10, 2022

Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

December 02, 2022

Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts

From Beam Therapeutics

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 13, 2022 ↗

December 13, 2022

Via Benzinga

BioNTech, Vertex Pharmaceuticals And Other Big Biotechnology Stocks From Benzinga's Most Accurate Analysts ↗

December 02, 2022

Although US stocks closed mixed on Thursday, but healthcare stocks recorded gains, gaining over 0.2% in the previous session. Biotechnology stocks were among the top performers in the sector, adding...

Via Benzinga

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

December 02, 2022

From Beam Therapeutics

Via GlobeNewswire

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

November 30, 2022

From Beam Therapeutics

Via GlobeNewswire

A Sitcom Character Inspired This Investor ↗

November 26, 2022

Plus, a look at the "Buffett premium" that investors give to Berkshire Hathaway stock.

Via The Motley Fool

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

November 14, 2022

BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States

From Beam Therapeutics

Via GlobeNewswire

Unity Software, Amazon, Doximity And Other Big Gainers From Friday ↗

November 14, 2022

U.S. stocks closed higher on Friday, with the Nasdaq Composite jumping more than 200 points. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

Beam Therapeutics to Participate in Upcoming Investor Conferences

November 09, 2022

From Beam Therapeutics

Via GlobeNewswire

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗

November 08, 2022

Gainers

Via Benzinga

Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session ↗

November 07, 2022

Gainers Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.